Extrinsic interstitial lung disease activity markers
https://doi.org/10.18093/0869-0189-2016-26-2-180-185
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
The aim of this study was to investigate values of pulmonary fibrosis markers alveomucin and KL-16 and the airway damage marker CC-16 for evaluating activity and progressing of extrinsic interstitial lung diseases (ILD) in dependence on etiology. Methods. Levels of Krebs von den Lungen-6 glycoprotein (KL-6), alveomucin and Clara cell protein (CC16) were measured using the ELISA method. The study involved 13 patients with pneumoconiosis, 26 patients with extrinsic allergic alveolitis (EAA) and 20 patients with extrinsic toxic alveolitis (ETA) both in active and stable status. Results. KL-6 and alveomucin were found to be more valuable markers for assessing activity of extrinsic fibrosing alveolitis compared to CC16. Alveomucin had higher specificity but lower sensitivity compared to KL-6. Conclusion. Alveomucin could be used as a screening test in cases with clinical susceptibility for extrinsic alveolitis. On contrary, KL-6 and alveomucin could be used for assessing therapeutic efficacy of EAA and ETA.
About the Authors
G. P. OrlovaRussian Federation
MD, Chief Scientist, Research Institute of interstitial and orphan lung diseases, Research Clinical Center, Academician I.P.Pavlov First Saint-Petersburg State Medical University, Healthcare Ministry of Russia; tel.: (812) 499-68-02;
E. A. Surkova
Russian Federation
PhD in Biology, Senior Researcher at Laboratory of Diagnosis of Autoimmune Diseases, Research Center of Molecular Medicine, Academician I.P.Pavlov First Saint-Petersburg State Medical University, Healthcare Ministry of Russia; tel.: (812) 338-71-94;
S. V. Lapin
Russian Federation
PhD, Head of Laboratory of Diagnosis of Autoimmune Diseases, Research Center of Molecular Medicine, Academician I.P.Pavlov First Saint-Petersburg State Medical University, Healthcare Ministry of Russia; tel.: (812) 338-71-94;
References
1. Il'kovich M.M. Terminology and .characterization. In: M.M.Il'kovich, ed. Disseminated lung diseases. Moscow: GEOTAR-Media; 2011: 10-13 (in Russian).
2. Kinnula V.L., Ishikawa N., Bergmann U. et al. Proteomic approaches for studying human parenchymal lung diseases. Exp. Rev. Proteomics. 2009; l (6): 619-629.
3. Nukiwa T. The role of biomarkers in management of interstitial lung disease: implication of biomarkers derived from type II pneumocytes. In: Du Bois R.M., Richeldi L., eds. Interstitial Lung Disease. Eur. Respir. Mon. UK.: ERS Journals Ltd; 2009, 46: 47-66.
4. Hesselstrand R., Wildt M., Bozovic G. et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. Respir. Med. 2013; 107 (7): 1079-1086.
5. Xu L., Yan D.R., Zhu S.L. et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation. Eur. Rev. Med. Pharmacol. Sci. 2013; 17 (22): 3073-3077.
6. Fazlyeva R.M., Mavziutova G.A., Kuzovkina O.Z. Clinical and diagnostic value of the determination of alveomucin in patients with community-acquired pneumonia. Klin. Lab. Diagn. 2010; 3: 51-53.
7. Zheng D., Limmon G.V., Yin L. et al. A cellular pathway involved in Clara cell to alveolar type II cell differentiation after severe lung injury. PLoS One 2013; 8 (8): e71028.
8. Kropski J., Fremont R., Calfee C., Ware L. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest. 2009; 135 (6): 1440-1447.
9. Ishikawa N., Hattori N., Yokoyama A., Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir. Invest. 2012; 50 (1): 3-13.
10. Ichiyasu H., Ichikado K., Yamashita A. et al. Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in non- specific interstitial pneumonia. Respiration. 2012; 83: 190-197.
11. Ley B., Brown K., Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. American journal of physiology. Lung cellular and molecular physiology."Am. J. Physiol. Lung Cell. Mol. Physiol. 2014; 307: L681-L691.
12. Takahashi T., Munakata M., Ohtsuka Y. et al. Serum KL-6 concentrations in dairy farmers. Chest. 2000; 118: 445-450.
13. Ohnishi H., Miyamoto S., Kawase S. et al. Seasonal variation of serum KL-6 concentrations is greater in patients with hypersensitivity pneumonitis. BMC Pulm. Med. 2014; 7 (14): 129. https://doi.org/10.1186/1471-2466-14-129.
14. Kawase S., Hattori N., Ishikawa N. et al. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced inter Bronchiolar Clara cells play a critical role in lung homoeostasis interstitial lung disease. Respir. Res. 2011; 12: 97. http://respiratory-research.com/content/12/1/97
15. Ohnishi H., Yokoyama A., Yasuhara Y. et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003; 58: 872-875.
16. Doishita S., Inokuma S., Asashima H. et al. Serum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseases. Intern. Med. 2011; 50 (23): 2889-2892.
17. Petrek M.., Hermans C., Kolek V. et al. Clara cell protein (CC16) in serum and bronchoalveolar lavage fluid of subjects exposed to asbestos. Biomarkers. 2002; 7 (1): 58-67.
18. Wang S.X.., Liu P., Wei M.T. et al. Roles of serum Slara cell protein 16 and surfactant protein-D in the early diagnosis and progression of silicosis. J. Occup. Environ. Med. 2007; 49 (8): 834-839.
19. Hałatek T., Trzcinka-Ochocka M., Matczak W., Gruchała J. Serum Clara cell protein as an indicator of pulmonary impairment in occupational exposure at aluminum foundry. Int. J. Occup. Med. Environ. Health. 2006; 19 (4): 211-223.
20. Quintar A.A., Leimgruber C., García L. et al. Restoration of the normal Clara cell phenotype after chronic allergic inflammation. Int. J. Exp. Pathol. 2013; 94 (6): 399-411.
Review
For citations:
Orlova G.P., Surkova E.A., Lapin S.V. Extrinsic interstitial lung disease activity markers. PULMONOLOGIYA. 2016;26(2):180-185. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-2-180-185
ISSN 2541-9617 (Online)